Agenus Inc. shares rose sharply in premarket trading after the biotechnology company said it had secured an $85 million private placement with the potential to grow into a $340 million package. The move gives the company a stronger funding base as it pushes ahead with its clinical pipeline.
According to finance.yahoo.com, the stock climbed 13% before the opening bell following the announcement. The financing includes purchase warrants that could bring in an additional $255 million if they are fully exercised.
Who Backed the Deal
The private placement was led by Commodore Capital, with participation from both existing and new institutional investors. Those investors include RA Capital Management, TCGX, Invus and Ligand Pharmaceuticals.
Company management said the proceeds will mainly support the Phase 3 ROBBIN clinical trial. If every warrant is exercised, Agenus expects the transaction to fund operations through the end of 2031.
| Financing Component | Amount | Details |
|---|---|---|
| Private placement | $85 million | Initial funding secured by Agenus |
| Purchase warrants | $255 million | Potential additional proceeds if fully exercised |
| Total potential package | $340 million | Combined value of the transaction |
Pipeline Priorities Are Shifting
Alongside the financing, Agenus said it plans to stop financial support for the BATTMAN Phase 3 study, which is evaluating a treatment for late-line metastatic microsatellite stable colorectal cancer. The company said it is redirecting resources toward programs it believes offer stronger long-term opportunities.
The new cash position gives Agenus more flexibility as it continues developing its late-stage clinical portfolio while extending its projected runway. Investors responded to that combination of fresh funding and narrower spending priorities with a strong premarket move higher.
